TRPV2 and breast carcinoma: Antimicrobial peptide LL-37, which is released from infiltrating immune cells, is able to activate TRPV2 and the Ca2+-activated K+ channel (KCa1.1) in different breast cancer cell lines leading to increased migration [62].